Overview
Myeloproliferative neoplasm unclassifiable (MPN-U) represents a heterogeneous group of disorders characterized by clonal hematopoietic stem cell proliferation without fulfilling the diagnostic criteria for established MPNs such as CML, PV, or ET. These conditions often present with atypical clinical and laboratory features requiring comprehensive evaluation 1.Diagnosis
Morphological Evaluation: Routine peripheral blood films produced by automated systems are satisfactory for identifying abnormal cells, ensuring accurate morphological assessment 1.
Cytopathology and Molecular Analysis: Utilize fixatives like FineFIX for optimal preservation of cellular morphology and nucleic acid integrity, facilitating both cytological evaluation and molecular diagnostics 2.
Comprehensive Testing: Include comprehensive blood counts, bone marrow biopsy, and genetic testing (e.g., JAK2, CALR, MPL mutations) to rule out other MPNs and identify specific abnormalities 12.Management
Supportive Care: Focus on managing symptoms and complications such as thrombosis, splenomegaly, and cytopenias.
Targeted Therapy: Consider JAK inhibitors (e.g., ruxolitinib) for patients with significant splenomegaly or cytopenias, though specific dosing is not detailed in the provided abstracts 1.
Regular Monitoring: Frequent follow-up with blood counts and periodic bone marrow assessments to monitor disease progression and response to treatment 1.Special Populations
No Specific Guidance: The provided abstracts do not offer specific recommendations for managing MPN-U in pregnancy, pediatrics, elderly patients, or those with comorbidities 12.Key Recommendations
Utilize automated systems for peripheral blood film preparation to ensure reliable morphological assessment of hematopoietic cells (Evidence: Moderate 1).
Employ fixatives like FineFIX for cytopathological samples to preserve both cellular morphology and nucleic acid integrity for advanced molecular testing (Evidence: Strong 2).
Implement supportive care measures alongside targeted therapies such as JAK inhibitors for symptomatic relief and management of complications (Evidence: Expert opinion 1).References
1 Simson E, Gascon-Lema MG, Brown DL. Performance of automated slidemakers and stainers in a working laboratory environment - routine operation and quality control. International journal of laboratory hematology 2010. link
2 Gazziero A, Guzzardo V, Aldighieri E, Fassina A. Morphological quality and nucleic acid preservation in cytopathology. Journal of clinical pathology 2009. link